Tender · Closed · Request for Proposal
Pralidoxime
Department of National Defence (DND)
- Closed
- January 22, 2026
- January 22, 2026 at 14:00
- Published
- December 1, 2025
- amended January 22, 2026
- Type
- Goods
- Competitive - Traditional
- Delivery
- Outside Canada
CanadaBuys tender notices published since Aug 2022; open as of October 12, 2026. Source: Public Services and Procurement Canada, CanadaBuys open data.
What it is
- Reference
- cb-61-23323223 · solicitation W6369-26-A033
- Commodity (UNSPSC)
- 51000000 Drugs and Pharmaceutical Products
- Topic
- Drugs and pharmaceuticals
- Delivery regions
- Outside Canada
- Trade agreements
- Please refer to Tender Description or Tender Documents
- How the winner is picked
- Lowest Price What this means
The Department of National Defence (DND) through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, has a requirement for Pralidoxime for the treatment of Canadian Armed Forces (CAF) members suspected of exposure to chemical warfare agents.
The initial requirement is for the delivery of 1,025 doses to be delivered before 31 March 2026. Optional requirements of 4,100 doses to be requested and delivered between 01 April 2026 and 31 March 2030.
There are no security requirements associated with this requirement.
The Crown retains the rights to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
Policy on Reciprocal Procurement: This solicitation of offers is open only to Canadian suppliers (if subject to any international trade agreement(s)): and to Suppliers of an applicable trading partner.
Excerpt of the buyer’s description, with contact details left out. The notice on CanadaBuys is the official version.
Who won the last ones like it
Recent CanadaBuys award notices with the same commodity code.
| Awarded | Supplier | What | Buyer | Value |
|---|---|---|---|---|
| Aug 2026 | Emergent BioSolutions Canada Inc. | SO - Naloxone Nasal Spray - Emergent BioSolutions Canada Inc | Royal Canadian Mounted Police (RCMP) | $3,000,000 |
| Apr 2026 | McKesson Canada Corporation | 21120-268734 Cystic Fibrosis Medications NISO | Correctional Service of Canada (CSC) | $4,000,000 |
| Apr 2026 | PRAXES Medical Group | K4E21-260484 REMOTE MEDICAL HEALTH CARE SUPPORT WITH MEDICAL SUPPLY KITS | Department of the Environment (ECCC ) | $79,147 |
| Apr 2026 | GlaxoSmithKline Inc. | Hepatitis B Vaccines GSK | Department of Public Works and Government Services (PSPC) | $9,462,827 |
| Apr 2026 | Merck Canada Inc. | Hepatitis B Vaccines Merck | Department of Public Works and Government Services (PSPC) | $3,855,797 |
| Mar 2026 | GlaxoSmithKline Inc. | Contract (GSK) - Supply Pertussis-containing vaccines | Department of National Defence (DND); Correctional Service of Canada (CSC); Department of Health (HC) | $29,400,277 |
| Mar 2026 | Sanofi Pasteur Limited/Sanofi Pasteur Limitee | Contract (Sanofi) - Supply Pertussis-containing vaccines | Correctional Service of Canada (CSC); Department of Health (HC); Department of National Defence (DND) | $37,781,553 |
| Feb 2026 | Emergent Product Development Gaithersburg Inc | ACAM2000-2nd Generation Smallpox Vaccine | Public Health Agency of Canada (PHAC) | $34,175,344 |
| Feb 2026 | Emergent BioDefense Operations Lansing | Tembexa (brincidofovir) Smallpox antiviral | Public Health Agency of Canada (PHAC) | $12,148,810 |
| Feb 2026 | GlaxoSmithKline Inc. | Meningococcal B Vaccine 2026 - GSK | Department of Public Works and Government Services (PSPC) | $3,147,955 |
| Oct 2025 | Not named here | Public Health Agency of Canada (PHAC) | $486,840 | |
| Jun 2025 | Moderna Biopharma Canada Corporation | COVID-19 Vaccines | Department of Public Works and Government Services (PSPC) | $360,542,980 |
| Jun 2025 | Pfizer Canada ULC | COVID-19 Vaccines | Department of Public Works and Government Services (PSPC) | $218,379,736 |
| May 2025 | Emergent BioSolutions Canada | 6D012-247322 - Vendor Managed - 3 Streams | Public Health Agency of Canada (PHAC) | $351,000 |
| May 2025 | Biogénesis Bagó S.A. | Foot and Mouth Disease Vaccine Bank | Canadian Food Inspection Agency (CFIA) | $9,397,000 |
Values as awarded, from $79,147 to $360,542,980.
Who wins most in this commodity class
Suppliers with the most award notices in the same six-digit UNSPSC class since 2022. Notices that give no value count in Awards, not in Total.
| Supplier | Awards | Total |
|---|---|---|
| GlaxoSmithKline Inc. | 7 | $128M |
| Emergent BioSolutions Canada Inc. | 5 | $85.4M1 not stated |
| Merck Canada Inc. | 4 | $370M |
| Pharmascience Inc. | 4 | $4.3M |
| Sanofi Pasteur Limited/Sanofi Pasteur Limitee | 3 | $79.6M |
| Natco Pharma (Canada) Inc. | 3 | $23.2M |
| Sandoz Canada Inc. | 3 | $5.7M |
| Pfizer Canada ULC | 2 | $258M |
| Emergent Product Development Gaithersburg Inc | 2 | $87.5M |
| HEYL Chem.-pharm. Fabrik GmbH & Co. KG | 2 | $19.9M |
CanadaBuys award notices since Aug 2022. They overlap the Treasury Board contract figures and are never added to them. Source: CanadaBuys open data, October 12, 2026.